Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

PURPOSE: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switch...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Katz, Gregory, Springs, Clark L, Craven, E Randy, Montecchi-Palmer, Michela
Aineistotyyppi: Teksti
Kieli:English
Julkaistu: Dove Medical Press 2010
Aiheet:
Original Research
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993125/
https://www.ncbi.nlm.nih.gov/pubmed/21151330
http://dx.doi.org/10.2147/OPTH.S14113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993125/
https://www.ncbi.nlm.nih.gov/pubmed/21151330
http://dx.doi.org/10.2147/OPTH.S14113

Samankaltaisia teoksia